RSS-Feed abonnieren
DOI: 10.1055/a-1244-1760
Pain and Neuropathic Pain in Rheumatic Diseases
Bedeutung des neuropathischen Schmerzes bei rheumatischen Erkrankungen![](https://www.thieme-connect.de/media/rheuma/202005/lookinside/thumbnails/2020-06-0650_10-1055-a-1244-1760-1.jpg)
Abstract
Pain is a challenge to rheumatologists. Not only patients with active arthritis but also patients with a good therapeutic response and even in remission complain of persistent joint pain. It has been proposed that a chronic pain stimulus may have a greater impact in a chronic inflammatory state, and the process towards a pain condition may be influenced by individual predisposition for development of chronic pain. In addition, features of peripheral pain processing may be exacerbated by inflammation, and disturbed pain processing may be a feature contributing to widespread pain. Furthermore, a neuropathic component may be part of the total pain experience of our patients. There are many different strategies of pain therapy in patients with rheumatic diseases, such as pharmacological and non- pharmacological modalities.
Zusammenfassung
Chronische Schmerzen sind eine Herausforderung im Alltag der rheumatologischen Praxis. Nicht nur die Patienten mit aktiver rheumatischen Erkrankungen, sondern auch die Patienten in Remission leiden an Schmerzen. Entzündliche Veränderungen können die individuelle Schmerzempfindlichkeit verstärken. Störungen der peripheren Schmerzregulation führen zur Verbreitung und Verstärkung der Schmerzempfindlichkeit und können als Folge die Persistenz der Schmerzen unterstützen. Bei vielen Patienten mit rheumatischen Erkrankungen und chronischen Schmerzen spielt ein neuropathischer Schmerz eine Rolle bei der Schmerzausprägung. Pharmakologische und nicht pharmakologische Methoden stehen als therapeutische Optionen zur Verfügung.
Publikationsverlauf
Artikel online veröffentlicht:
14. Oktober 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Smith BH, Fors EA, Korwisi B. et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: applicability in primary care. Pain 2019; 160: 83-87
- 2 Trouvin AP, Perrot S. New concepts of pain. Best Pract Res Clin Rheumatol 2019; 33: 101415
- 3 Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol 2019; 33: 101423
- 4 Lampa J. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol 2019; 33: 101439
- 5 Scholz J, Finnerup NB, Attal N. et al. Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain 2019; 160: 53-59
- 6 Thorpe J, Shum B, Moore RA. et al. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev 2018; 2: CD010585
- 7 Honda Y, Sakamoto J, Hamaue Y. et al. Effects of Physical-Agent Pain Relief Modalities for Fibromyalgia Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Res Manag 2018; 2018: 2930632
- 8 Audede M. Does the IASP definition of pain need updating?. Pain Rep 2019; 4: e777
- 9 Williams AC, Craig KD. Updating the definition of pain. Pain 2016; 157: 2420-2423
- 10 Aydede M, Shriver A. Recently introduced definition of “nociplastic pain” by the International Association for the Study of Pain needs better formulation. Pain 2018; 159: 1176-1177
- 11 Freynhagen R, Parada HA, Calderon-Ospina CA. et al. Current understanding of the mixed pain concept: a brief narrative review. Curr Med Res Opin 2019; 35: 1011-1018
- 12 Treede RD, Rief W, Barke A. et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019; 160: 19-27
- 13 Nugraha B, Gutenbrunner C, Barke A. et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: functioning properties of chronic pain. Pain 2019; 160: 88-94
- 14 Nicholas M, Vlaeyen JWS, Rief W. et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain 2019; 160: 28-37
- 15 Perrot S, Cohen M, Barke A. et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic secondary musculoskeletal pain. Pain 2019; 160: 77-82
- 16 Scholz J, Finnerup NB, Attal N. et al. Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG) The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain 2019; 160: 53-59
- 17 Bouhassira D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris) 2019; 175: 16-25
- 18 Cavalli E, Mammana S, Nicoletti F. et al. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol 2019; 33: 2058738419838383
- 19 CADTH Rapid Response Reports. Diagnostic Methods for Neuropathic Pain: A Review of Diagnostic Accuracy. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015
- 20 Vitali C, Del Papa N. Pain in primary Sjögren’s syndrome. Best Pract Res Clin Rheumatol 2015; 29: 63-70
- 21 Calvo M, Davies AJ, Hébert HL. et al. The Genetics of Neuropathic Pain from Model Organisms to Clinical Application. Neuron 2019; 104: 637-653
- 22 Yin Y, Yi MH, Kim DW. Impaired Autophagy of GABAergic Interneurons in Neuropathic Pain. Pain Res Manag 2018; 2018: 9185368
- 23 Zheng LX, Li KX, Hong FF. et al. Pain and bone damage in rheumatoid arthritis: role of leukotriene B4. Clin Exp Rheumatol 2019; 37: 872-878
- 24 Malcangio M. Role of the immune system in neuropathic pain. Scand J Pain 2019; 20: 33-37
- 25 Davies AJ, Rinaldi S, Costigan M. et al. Cytotoxic Immunity in Peripheral Nerve Injury and Pain. Front Neurosci 2020; 14: 142
- 26 Sántha P, Dobos I, Kis G. et al. Role of Gangliosides in Peripheral Pain Mechanisms. Int J Mol Sci 2020; 21: pii: E1005
- 27 Mohd Noh AS, Ismail CAN. A Review on Chronic Pain in Rheumatoid Arthritis: A Focus on Activation of NR2B Subunit of N-Methyl-D-Aspartate Receptors. Malays J Med Sci 2020; 27: 6-21
- 28 Ueda H. Systems Pathology of Neuropathic Pain and Fibromyalgia. Biol Pharm Bull 2019; 42: 1773-1782
- 29 Viswanath O, Urits I, Burns J. et al. Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations. Adv Ther 2020; 37: 1946-1959
- 30 Spallone V, RMorganti R, CD’Amato C. et al. Validation of DN4 as a Screening Tool for Neuropathic Pain in Painful Diabetic Polyneuropathy. Diabet Med 2012; 29: 578-585
- 31 Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Current Medical Research and Opinion 2006; 22: 1555-1565
- 32 Bennett M. The LANSS Pain Scale: The Leeds Assessment of Neuropathic Symptoms and Signs. Clinical Trial Pain 2001; 92: 147-157
- 33 Freynhagen R, Baron R, Ulrich Gockel U. et al. PainDETECT: A New Screening Questionnaire to Identify Neuropathic Components in Patients With Back Pain. Curr Med Res Opin 2006; 22: 1911-1920
- 34 Krause SJ, Backonja MM. Development of a Neuropathic Pain Questionnaire. Clin J Pain 2003; 19: 306-314
- 35 Mathieson S, Maher CG, Terwee CB. et al. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol 2015; 68: 957-966
- 36 Freynhagen R, Tölle TR, Gockel U. et al. The painDETECT project−far more than a screening tool on neuropathic pain. Curr Med Res Opin 2016; 32: 1033-1057
- 37 Garcia-Larrea L, Hagiwara K. Electrophysiology in diagnosis and management of neuropathic pain. Rev Neurol (Paris) 2019; 175: 26-37
- 38 Ørstavik K, Kleggetveit IP, Jørum E. Microneurography and research on peripheral neuropathic pain. Tidsskr Nor Laegeforen 2013; 133: 302-305
- 39 Gwathmey KG, Pearson KT. Diagnosis and management of sensory polyneuropathy. BMJ 2019; 365: l1108 doi:10.1136/bmj.l1108
- 40 Whittle SL, Colebatch AN, Buchbinder R. et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford) 2012; 51: 1416-1425
- 41 Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Intern Med 2019; 79: 695-701
- 42 Arnold LM, Choy E, Clauw DJ. et al. An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr Med Res Opin 2018; 34: 1397-1409
- 43 Noori SA, Aiyer R, Yu J. et al. Nonopioid versus opioid agents for chronic neuropathic pain, rheumatoid arthritis pain, cancer pain and low back pain. Pain Manag 2019; 9: 205-216
- 44 Derry S, Phillips T, Moore RA. et al. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7: CD011789
- 45 Moore RA, Derry S, Aldington D. et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012; 12: CD008242
- 46 Fattori V, Zaninelli TH, Rasquel-Oliveira FS. et al. Specialized pro-resolving lipid mediators: A new class of non-immunosuppressive and non-opioid analgesic drugs. Pharmacol Res 2020; 151: 104549
- 47 Chakravarthy K, Chen Y, He C. et al. Stem Cell Therapy for Chronic Pain Management: Review of Uses, Advances, and Adverse Effects. Pain Physician 2017; 20: 293-305
- 48 Sałat K, Jakubowska A, Kulig K. Zucapsaicin for the treatment of neuropathic pain. Expert Opin Investig Drugs 2014; 23: 1433-1440
- 49 Szok D, Tajti J, Nyári A. et al. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav Neurol 2019; 21: 8685954
- 50 Van Laake-Geelen CCM, Smeets R, Quadflieg S. et al. The effect of exercise therapy combined with psychological therapy on physical activity and quality of life in patients with painful diabetic neuropathy: a systematic review. Scand J Pain 2019; 19: 433-439
- 51 Eccleston C, Hearn L, Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. The Cochrane Database of Systematic Reviews 2015; 10: CD011259
- 52 Akyuz G, Kenis O. Physical Therapy Modalities and Rehabilitation Techniques in the Management of Neuropathic Pain. Am J Phys Med Rehabil 2014; 93: 253-259
- 53 Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. Pain Res Manag 2018; 2018: 8564215
- 54 Smolen J, Landewé R, Bijlsma J. et al. EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update . Ann Rheum Dis 2017; 76: 960-977
- 55 Mousa A, Bakhiet M. Role of Cytokine Signaling During Nervous System Development. Int J Mol Sci 2013; 14: 13931-14057
- 56 Alten R, Mischkewitz M, Stefanski AL. et al. Janus kinase inhibitors : State of the art in clinical use and future perspectives. Z Rheumatol 2020; 79: 241-254
- 57 Witte T. JAK Inhibitors in Rheumatology. Dtsch Med Wochenschr 2019; 144: 748-752
- 58 Strand V, van der Heijde D, Tanaka Y. et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clin Exp Rheumatol 2019; 19. Online ahead of print
- 59 Boyce EG, Vyas D, Rogan EL. et al. Impact of Tofacitinib on Patient Outcomes in Rheumatoid Arthritis−Review of Clinical Studies. Patient Relat Outcome Meas 2016; 7: 1-12
- 60 Fautrel B, Kirkham B, Pope JE. et al. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients With Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses From RA-BEAM. J Clin Med 2019; 8: 1394